Weight loss drugs could soon be used to treat these seven other health conditions - Eli Lilly and Novo Nordisk are actively ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

A new analysis of 11 global studies shows that people tend to regain lost weight after stopping anti-obesity medications like ...

Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials, Lilly said on Friday. Below are other conditions obesity treatments are being ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to ...